idecabtagene vicleucel CAR-T
Selected indexed studies
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. (N Engl J Med, 2021) [PMID:33626253]
- Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. (Future Oncol, 2022) [PMID:34854741]
- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. (J Clin Oncol, 2023) [PMID:36623248]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Impact of Manufacturing Procedures on CAR T Cell Functionality. (2022) pubmed
- Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma. (2025) pubmed
- Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis. (2024) pubmed
- Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. (2025) pubmed
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. (2021) pubmed
- Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. (2022) pubmed
- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. (2023) pubmed
- Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. (2024) pubmed
- Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. (2025) pubmed
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. (2023) pubmed